Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.

Spotlight on pembrolizumab in the treatment of advanced melanoma. Drug Des Devel Ther (2015) 0.90

Targeting antisense mitochondrial ncRNAs inhibits murine melanoma tumor growth and metastasis through reduction in survival and invasion factors. Oncotarget (2016) 0.85

Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. J Clin Med Res (2015) 0.85

The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget (2015) 0.83

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer (2016) 0.82

Serpine2, a potential novel target for combating melanoma metastasis. Am J Transl Res (2016) 0.78

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) (2017) 0.76

Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse. Nat Commun (2016) 0.76

Effects of nuclear factor-κB and ERK signaling transduction pathway inhibitors on human melanoma cell proliferation in vitro. Oncol Lett (2015) 0.76

The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Oncoimmunology (2016) 0.76

Muc1 promotes migration and lung metastasis of melanoma cells. Am J Cancer Res (2015) 0.76

The calcium pump plasma membrane Ca(2+)-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin. Sci Rep (2016) 0.75

The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. J Immunol Res (2016) 0.75

Editorial: "Cancer Immunotherapy: Lights and Shadows". Front Immunol (2015) 0.75

Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors. Cancer Res (2017) 0.75

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma. Front Immunol (2017) 0.75

Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94

Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88

Taking dendritic cells into medicine. Nature (2007) 11.82

Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63

Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36

Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73

Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med (2006) 3.47

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 3.37

Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood (2007) 3.13

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res (2010) 3.02

BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer (2012) 2.55

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2012) 2.28

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11

BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol (2011) 2.10

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res (2010) 2.02

Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 1.95

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 1.94

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (2006) 1.75

Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood (2012) 1.74

Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72

Clinical use of dendritic cells for cancer therapy. Lancet Oncol (2014) 1.63

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma (2008) 1.63

Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn (2012) 1.59

Antigens for cancer immunotherapy. Semin Immunol (2008) 1.46

Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.44

Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol (2003) 1.40

A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40

Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One (2011) 1.38

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res (2011) 1.29

Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel) (2010) 1.22

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res (2014) 1.21

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res (2014) 1.19

Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol (2014) 1.07

The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07

Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep (2012) 1.05

Mechanisms of interferon-induced cell cycle arrest. Front Biosci (2000) 1.03

A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother (2006) 0.99

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother (2008) 0.96

A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med (2008) 0.95

Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med (2007) 0.93

Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol Ther (2007) 0.93

Lessons from cancer immunoediting in cutaneous melanoma. Clin Dev Immunol (2012) 0.91

Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard. Oncoimmunology (2013) 0.90

Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines (2005) 0.90

MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro. J Invest Dermatol (2011) 0.89

Apoptosis and cell growth inhibition as antitumor effector functions of interferons. Med Oncol (2001) 0.89

Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol (1994) 0.88

Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. J Pharm Sci (2009) 0.88

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology (2014) 0.87

VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res (2008) 0.87

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology (2012) 0.87

Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int (2013) 0.86

In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients. Melanoma Res (2010) 0.85

The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma. BMC Cancer (2014) 0.83

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology (2014) 0.82

Involvement of oxidative and nitrosative stress in modulation of gene expression and functional responses by IFNgamma. Int Immunol (2007) 0.81

Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma. Cancer Immunol Immunother (2012) 0.77

Melanoma genetics: the other side. Clin Dermatol (2013) 0.77

In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-α alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression. J BUON (2013) 0.76